Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
NCT ID: NCT04213326
Last Updated: 2024-06-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6400 participants
OBSERVATIONAL
2019-11-18
2021-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Potential participants will be asked questions to confirm their eligibility by a nurse navigator, study staff member, or physician.
Informed consent will be carried out for eligible subjects in accordance with applicable federal regulations and International Council for Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines.
Subjects will then complete a survey, and study staff will draw 60 mL of blood and measure the height and weight of the subject.
Where available, data from the medical records of the cancer subjects will reviewed and collected. In addition, non-cancer subjects will be requested to allow access to their medical records as an optional portion of their informed consent.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
NCT00001163
Study of Healthy Cohort for Early Detection of Cancer
NCT05193305
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
NCT00003329
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
NCT05833360
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
NCT04354064
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Potential participants will be asked questions to confirm their eligibility by a nurse navigator, study staff member, or physician to document screening including date of upcoming therapy or surgery for cancer patients if one has been scheduled, before providing informed consent to participate in the study. Study procedures outside of the pre-screening for eligibility will not be performed prior to the subject providing consent. Informed consent will be carried out in accordance with applicable federal regulations and International Council for Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines. Prior to signing the informed consent form (ICF), potential participants will confirm that they understand the study and that they have no questions about the study.
The ICF may be offered by paper or electronically with the option to also review a paper copy provided by the nurse navigator or study coordinator either face-to-face on a tablet or via email. Potential participants will be given a phone number to call with any study specific questions. Copies of all signed consent forms will be stored centrally in a secure environment, and signed consent forms will thereby be available for verification by Thrive or its designee at any time.
Once the subject completes the survey, study staff will complete the blood draw and collect height and weight data. For some participants, their contact information and unique study identifier (ID) will be sent securely to a third-party vendor who will contact the subject within 24 hours to schedule the blood draw and height and weight measurements at a location convenient to the subject.
For all subjects, study staff and the third-party vendor performing the blood collection will verify the following before performing the blood draw and height and weight measurements: participant identity and age against a form of identification, that consent to participate has been given, that the participants in the cancer arm are still treatment naïve, and that they do not have a fever that could be caused by an infection. The blood collection vendor will ensure all required data are captured and included with the blood sample, that the sample is collected and packaged according to laboratory manual specifications, and that the sample is shipped to the indicated processing lab with the required expediency. Following all study visits, study staff and third party vendor staff will complete a visit checklist confirming all of the study activities that occurred.
Subjects in the Cancer cohort will be identified via nurse navigation, study staff or oncology physicians in local offices. The nurse navigator or study staff will verify eligibility through chart review and pre-screen, approach the subject about the study opportunity, and present the informed consent form. For participants enrolling electronically, participants will be presented with a secured tablet device on which the subject will watch a brief video about the study, read the informed consent and provide electronic consent. Some participants may also have the option of having the video, informed consent and survey emailed to them. Upon consent and enrollment, subjects will be assigned a unique subject study ID, which will be used to track the subject, their data and their biospecimen throughout study operations. Consented subjects will then be directed to complete a survey via the tablet device, email or paper. Participants will be allowed to skip questions in the survey or select the answer option "prefer not to answer." Subject data will be tracked in real-time by central study staff to ensure desired tumor type diversification and communicate enrollment strategy changes to the nurse navigators and study staff.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer Cohort
Subjects interested in the cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
No interventions assigned to this group
Non-Cancer Cohort
Subjects interested in the non-cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to understand the nature of this study and give written informed consent
CANCER COHORT:
Either of the following:
* Histologic diagnosis of cancer with no prior systemic or definitive therapy (any stage, including, inclusive of is-situ carcinoma)
Or
* Subject with high suspicion of cancer through radiological and/or clinical assessment who are scheduled for resection or biopsy within 6 weeks of study blood collection and have not received prior systemic or definitive therapy.
NON-CANCER COHORT
* No prior history of cancer
Exclusion Criteria
* Evidence of active febrile infection prior to blood draw.
* Women who are pregnant or breast-feeding.
* History of an allogeneic bone marrow, stem cell transplant, or solid organ transplant.
* Judgment by the Investigator or study staff of any other reason that would prohibit the inclusion of the subject in the study.
CANCER COHORT
* Subjects newly diagnosed with a hematologic malignancy, primary central nervous system tumor, prostate cancer, or skin cancer (including melanoma).
* History of, or currently receiving, systemic or definitive cancer treatment including curative surgical resection, chemotherapy, radiation therapy, immunotherapy, and hormone therapy.
NON-CANCER COHORT
• None
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Exact Sciences Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dax Kurbegov, MD
Role: PRINCIPAL_INVESTIGATOR
Sarah Cannon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sarah Cannon
Thousand Oaks, California, United States
Sarah Cannon
Denver, Colorado, United States
Sarah Cannon
Fort Walton Beach, Florida, United States
Sarah Cannon
Ocala, Florida, United States
Sarah Cannon
Pensacola, Florida, United States
Sarah Cannon
Augusta, Georgia, United States
Sarah Cannon
Macon, Georgia, United States
Sarah Cannon
Savannah, Georgia, United States
Sarah Cannon
Kansas City, Kansas, United States
Sarah Cannon
Overland Park, Kansas, United States
Sarah Cannon
Independence, Missouri, United States
Sarah Cannon
Las Vegas, Nevada, United States
Sarah Cannon
Nashville, Tennessee, United States
Sarah Cannon
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Post C, Braun TP, Etzioni R, Nabavizadeh N. Multicancer Early Detection Tests: An Overview of Early Results From Prospective Clinical Studies and Opportunities for Oncologists. JCO Oncol Pract. 2023 Dec;19(12):1111-1115. doi: 10.1200/OP.23.00260. Epub 2023 Oct 18.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEOR 24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.